Download Champions' TRP Europe 2025 Poster
Advancing Radiopharmaceutical Development with Translationally Relevant PDX Models
Radiolabeling and Preclinical Evaluation of Radiopharmaceuticals in Patient-Derived Xenograft (PDX) Animal Models
This poster highlights how Champions Oncology combines radiolabeling expertise with deeply characterized PDX models to advance radiopharmaceutical development. Our translational approach delivers insight into biodistribution, dosimetry, and efficacy across clinically relevant tumor types.Learning outcomes:
- Explore radiolabeling workflows using Lu-177, In-111, and Ac-225 across small molecules, peptides, and macromolecules with high radiochemical purity (≥99%).
- See biodistribution and efficacy results for 177Lu-PSMA-617 in PSMA+ prostate cancer PDX models.
- Review tumor regression data from a Deruxtecan-resistant gastric PDX model treated with 177Lu-labeled COmAb55.
- Learn how integrating radiopharmacology with PDX biology supports target validation and dose optimization.
- Discover how Champions Oncology’s platform bridges chemistry, biology, and translational relevance to accelerate clinical decision-making.
Download the Poster